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ABSTRACT
Background. Secondary angiosarcoma of the breast is a
rare but severe long-term complication of breast cancer
treated with breast-conserving surgery and radiotherapy.
We characterized a population-based cohort of patients
with secondary angiosarcomas from two tertiary hospitals
to investigate this complication with respect to surgical
treatment and outcome.
Methods. We identified 35 patients with a history of
radiation for breast cancer that developed angiosarcoma in
the irradiated field from 1990 to 2009. Of these, 31
underwent surgery and were included for analysis.
Results. Angiosarcoma developed after median 7 years
(range 3–25 years). R0 resection was obtained in 23 of 31
patients after primary treatment. Local recurrence developed
in 19 patients after median 6 months (range 1–89 months).
Regional and distant metastases occurred in 13 patients after
median 17 months (range 2–50 months); nine which also had
local recurrence. Patients whose local recurrence could be
operated on had a better survival after treatment than those
who were not considered for surgical treatment, median
34 months (range 6–84 months) compared with 6 months
(range 5–24 months). The median disease-free survival and
disease-specific survival was 16 and 37 months, respectively.
Conclusions. Despite R0 resection, two-thirds of the
patients developed a local recurrence. Survival among
those with local recurrence was better if the patient could
be treated with surgery. Overall, the prognosis was dismal
and median DSS was just over 3 years.
Breast-conserving treatment (BCT) with radiotherapy has
replaced mastectomy as the standard care for early-stage breast
cancer in the last few decades.1 Radiotherapy is usually
administered at a maximum of 50 Gy to the operated area, in
some cases with an extra booster of 10–20 Gy to the tumor
bed. The incidence of breast cancer is increasing; currently, it
affects one in ten women in the western world. Accordingly,
more secondary angiosarcomas have been reported, with a
cumulative incidence of 0.9 per 1,000 breast cancer cases over
15 years.2 The development of secondary angiosarcoma has
been linked to radiotherapy and lymphedema.3–5
Secondary angiosarcomas after BCT have an observed
median latency period of *4–8 years.6–10 Because of their
rarity and seemingly harmless presentation, frequently com-
prising painless and bruise like skin lesions, both patients and
doctors often neglect the initial symptoms and diagnosis is
delayed. Patients often have localized, but multifocally grow-
ing, disease that is confined to the breast at diagnosis. Surgery is
the mainstay of treatment and is usually performed with local
resection or mastectomy. The risk of local recurrence and
metastasis is high.9 There have been several studies of (neo-)
adjuvant chemotherapy, but the effects remain unclear.9,11,12
The poor outcome of secondary angiosarcoma is well
known, albeit mainly through numerous case reports.8,13,14
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Few have looked at the surgical treatment and outcome.15
We have performed a 2-center retrospective study to
characterize the disease with respect to treatment and




We identified all female patients with histopathologically
diagnosed angiosarcoma of the breast in the northern Dutch
Health Care Region (1.8 million inhabitants) and the
southern Swedish Health Care Region (1.7 million inhabit-
ants). The northern Dutch part of the nationwide network
and registry of histopathology and cytopathology in the
Netherlands (PALGA) (since 1971) and the southern
Swedish part of the national Swedish Cancer Registry (since
1958), and, in addition, the pathology registry (since 1960)
were used to identify all cases within the populations.
Patients with breast cancer diagnosed prior to angiosarcoma
were selected (n = 50). Prerequisites used for this study
were those proposed by Cahan et al.16 and modified by
Arlen et al.17: (1) a sarcoma arising within the field of
previous radiotherapy, (2) differing histology between the
secondary sarcoma and primary tumor, and (3) at least a
3-year latency period between radiation therapy and devel-
opment of the sarcoma. Under these criteria, 35 cases were
identified from 1990 to 2009. Surgery with curative intent
was performed on 31 patients. Data regarding the radio-
therapy dose, type of surgery for the angiosarcoma, local
recurrence, metastatic disease, and death were obtained from
hospital and primary care records.
Patient Characteristics
The median age of patients at the time of breast cancer
diagnosis was 59 years (range 42–77 years). As part of
breast cancer therapy, radiotherapy was administered at a
median dose of 50 Gy (range 45–70 Gy). Nearly one-third
of the patients received an extra radiation boost to the
tumor bed, resulting in a total dose of 66–70 Gy.
Outcome Measures
The endpoints of this study were disease-free survival
(DFS), disease-specific survival (DSS), time to local recur-
rence, and time to distant metastasis. DFS was defined as the
time from start of treatment to local recurrence, distant
metastasis, or last follow-up. DSS was defined as time from
diagnosis of secondary angiosarcoma to death due to angi-
osarcoma or last follow-up. Time to local recurrence was
defined as the time from treatment to radiological or path-
ological confirmation of local recurrence. Time to distant
metastasis was defined as the time from treatment of the
secondary angiosarcoma to radiological or pathological
confirmation of metastasis. In the text, surgical margins
were defined as R1 (microscopically intralesional) or R0
(microscopically free margin). The data are presented as
median and range, unless stated otherwise.
Statistical Analysis
The DFS and DSS were calculated according to the
Kaplan–Meier method. All analyses were performed using




In 13 of 35 patients, angiosarcoma presented as a blue or
red discoloration of the skin; in 14 patients, it started with a
tumor, and in eight patients, both discoloration and tumor
were present. The tumors had a median size of 4 cm (range
1–15 cm), with a multifocal appearance. The median time
from the administration of radiotherapy to the development
of angiosarcoma was 7 years (range 3–25 years), and the
median age of the patients when the angiosarcoma was
diagnosed was 67 years (range 47–89 years). Of the 35
patients, 31 underwent surgery with curative intent and
were included in the survival analysis. The four patients
who did not undergo surgery had metastatic or locally
advanced disease (Fig. 1).
Primary Treatment
The main surgical approaches used for resection of the
primary tumor of the secondary angiosarcoma were local
excision of the tumor (n = 7) (either due to previous
mastectomy as part of breast cancer treatment or the local
excision was performed outside our tertiary hospitals) and
mastectomy (n = 24) (Table 1). In all cases operated on at
the two tertiary centers, the aim was a minimum macro-
scopic margin of 2 cm. An R0 resection was achieved in 23
patients after primary treatment, seven patients were
operated on twice for primary tumor. A total of 16 cases
required reconstruction at treatment for the primary tumor,
and the choice of reconstruction was tailored to the size of
the defect. In 13 cases a split-thickness skin graft was used,
in 1 case reconstruction with a pedicled flap of the latiss-
imus dorsi and in 2 cases a combination of both techniques
were used for reconstruction.
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In addition to surgical treatment for the primary tumor,
one patient received neoadjuvant chemotherapy (adriamy-
cin 6 cycles) and one patient received adjuvant
radiotherapy (50.4 Gy) after intralesional surgery.
In our series, mastectomy achieved R0 margins at higher
rates than local resection (14 of 24 compared with 2 of 7).
In addition, in three patients excision of all irradiated tissue
was performed based on the radiotherapy field film,
achieving R0 resection in 2 cases.
Local Recurrence
After a median of 6 months (range 1–89 months), 19
patients developed a local recurrence. Of these, 14 had an
initial R0 resection. In patients with local recurrence, 11
patients underwent surgery, which resulted in R0 resectionFIG. 1 Patient with extensive angiosarcoma in both breasts
TABLE 1 Treatment and
outcome for primary
angiosarcoma disease
STSG split thickness skin graft









1 Mastectomy STSG R0 No Yes No
2 Mastectomy STSG R0a No Yes No
3 Mastectomy STSG R0 No No Yes
4 Mastectomy No R0 No No No
5 Mastectomy No R0 No No No
6 Mastectomy STSG R0a No Yes Yes
7 Mastectomy No R0 No No Yes
8 Mastectomy STSG R0 No Yes No
9 Mastectomy No R0 No Yes No
10 Local excision No R0a No Yes No
11 Mastectomy No R0 No No No
12 Mastectomy STSG R0 No Yes Yes
13 Mastectomy No R0a Radiotherapy Yes No
14 Local excision STSG R0 No No No
15 Mastectomy Muscle flap R2 Chemotherapy Yes Yes
16 Local excision No R0a No No No
17 Mastectomy STSG R2 No Yes Yes
18 Mastectomy No R2 No Yes No
19 Local excision STSG R2 No No Yes
20 Local excision No R0 No Yes No
21 Mastectomy STSG R1 No Yes No
22 Mastectomy No R0 No Yes Yes
23 Mastectomy No R2 No Yes Yes
24 Mastectomy No R0 No Yes No
25 Mastectomy STSG R0 No No Yes
26 Mastectomy STSG R2 No Yes Yes
27 Mastectomy STSG R0 No Yes Yes
28 Mastectomy No R0 No No No
29 Mastectomy Muscle flap ? STSG R0a No No No
30 Local excision No R2 No Yes Yes
31 Local excision Muscle flap ? STSG R0a No No No
2702 J. M. Seinen et al.
in ten patients. Adjuvant radiotherapy was administered to
one patient and adjuvant chemotherapy to one. Of the eight
patients not undergoing surgery, one received radiotherapy
and one both radiotherapy and chemotherapy (Table 2). The
reason for not performing surgery in five of eight patients
was concurrent metastasis, of whom four patients received
chemotherapy. In the remaining three cases, extensive local
disease was the reason not to perform surgery in 2 cases and
in 1 case the reason was unknown. Patients who underwent
surgery for local recurrence survived a median of 34 months
(range 6–84 months) after surgery, compared with 6 months
(5–24 months) for those who did not.
















1 R0 5 Local excision – – 14
2 R0 2 Local excision – – 34
3 R0 89 Local excision – – 63
4 R0 40 Local excision – – 20
5 R0 18 Local excision – – 49
6 R0 5 Local excision – – 6
7 R0 4 Mastectomy – – 57




9 R0 1 None – – 1
10 R1 86 None – – 2
Metastasis
1 R0 – – 17 (vertebrae) RT 20 Gy 20
2 R0 – – 2 (lung) RT 41 Gy 16
3 R0 – – 24 (axillary) Resection 29
4 R0 – – 50 (cerebral,
abdominal)
None 3
Local recurrence ? metastasis
1 R0 6 – 23 (lung) None 18
2 R0 8 Local excision 18 (vertebrae) RT 8 Gy 16
3 R1 2 None 2 (contralateral
breast)
Adriamycin (6 cycles); paclitaxel,
bevacizumab (5 cycles); cyclofosfamid
24
4 R1 12 None 8 (axillary) Resection, RT (dose unknown); adriamycin
(5 cycles); fluorouracil, farmorubicin,
cyclofosfamid (4 cycles)
14





6 R1 2 – 2 (contralateral
breast, sacrum)
None 1
7 R1 2 RT, dose unknown 2 (cerebral,
abdominal)
Cisplatin 5
8 R0 18 None 17 (axillary, lung) Resection ? RT 45 Gy;
doxorubicin ? isofosfamid (1 cycle);
gemzar, taxotere
8
9 R0 12 Local excision 41 (axillary) Resection ? RT 50 Gy;
doxorubicin ? ifosfamid
55
LR local recurrence, RT radiotherapy
a Recurrence: first appearing (local recurrence or distant metastasis)
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Metastatic Disease
There were nine patients who developed distant meta-
static disease, and four patients developed regional
metastatic disease after a median of 17 months (range
2–50 months). Of these patients nine also had a local
recurrence. In the four patients with regional metastatic
disease, resection of metastasis to lymph nodes was per-
formed, which led to 1 case of R0 resection, 2 cases of R1
resection, and 1 case with unknown margins. Patients with
regional metastasis who underwent surgery survived a
median of 20 months (range 8–29 months) after surgery,
compared with 5 months (range 1–24 months) for those
with distant metastasis who did not undergo surgery. Of
the 13 patients with metastases, six patients received che-
motherapy and six patients underwent radiotherapy
(Table 2).
Survival
With a median follow-up of 27 months (range
1–151 months), 21 of 31 patients died; 17 of the deaths
were due to angiosarcoma, three due to other diseases, and
one patient died of unknown cause. There were ten patients
still alive at last follow-up. Of these patients, nine had no
evidence of disease after a median follow-up of 53 months
(range 10–108 months). The remaining patient had local
disease after 7 years. Of the patients with metastasis, one
patient was still alive 2.5 years after surgery for regional
metastasis. The three patients who underwent excision of
all irradiated tissue, based on the radiation field films, with
R0 margins were alive after 2, 2.5, and 9 years with no
evidence of disease. For the total population, the median
DFS and DSS was 16 and 37 months, respectively
(Fig. 2a, b).
DISCUSSION
Although secondary angiosarcomas of the breast have
an approximate incidence of only 0.9 per 1,000 breast
cancer cases2, they are important because this disease has a
very poor prognosis and is related to a previous medical
treatment. In this study, two-thirds of the patients with
secondary angiosarcoma presented with the typical blue/
red discoloration of the skin, sometimes in combination
with palpable tumor. The lesions can be single or multiple
nodules, and papules or vesicles. One-third of the patients
presented solely with a tumor; therefore, suspicion of
secondary angiosarcoma should not rest only upon dis-
coloration of the skin. In any patients with discoloration
that does not disappear or tumor development within the
radiation field, a needle or open biopsy should be per-
formed. Mammography and/or MRI play only a limited
role in diagnostics, but MRI may be slightly better at
detecting an angiosarcoma.18,19 Since the first case of
secondary angiosarcoma of the breast was described in
1987, the prognosis has remained poor, with a median
survival of 1–3 years.5 In our population-based study, we
found similar median survivals of 16 and 37 months for
DFS and DSS, respectively. Only two of our 35 identified
patients presented with metastatic angiosarcoma, both died
of the disease within 6 months.
Compared with previously reported population-based
studies (Fodor et al. 2006, n = 8; Hodgson et al. 2007,
n = 31; and Marchal et al. 1999, n = 9)6,19,20, our cohort
had similar median ages at the time of diagnosis of breast
cancer (mean 60 years) and secondary angiosarcoma
(mean 68 years). To the best of our knowledge, this is the
equal largest study (n = 31) published for secondary
angiosarcoma developing in the irradiated field, but the





























FIG. 2 a DFS in months,
b DSS in months. a There were
patients alive without disease,
these are among the censored
cases
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Most secondary angiosarcomas present as localized
disease without metastasis. Nevertheless, they are difficult
to control and often recur locally.9 In our series, mastec-
tomy achieved R0 margins at higher rates than local
resection. In addition, three patients had mastectomy with
resection of all irradiated tissue as primary treatment, R0
margins achieved in 2 cases and are alive after 2–9 years
without evidence of disease.
Of the 31 patients who underwent surgery, the primary
treatment resulted in R0 resections in 23 patients. Despite
this, nearly two-thirds of these patients developed a local
recurrence. We believe this to be due to the multifocal growth
of angiosarcoma and tumor tissue left behind, even if the
surgical margins are considered free. In this study, 11 of 19
patients with a local recurrence were considered eligible for
surgery. The five patients with metastasis and three patients
with locally extensive disease were not considered suitable
for surgical treatment. The patients selected for surgery for
local recurrence survived longer than those who did not. This
difference we believe is due to different stages of tumor, and
hence surgery has not necessarily made the difference.
However, we conclude that local recurrence per se should not
disqualify from aiming at surgery with curative intent.
In addition, four patients with lymph node metastases
underwent surgery. Of these, two patients were without
evidence of disease at the last follow-up, more than 2 years
after surgery. The other two patients died of tumor after 8
and 14 months because of their angiosarcoma.
In other types of soft tissue sarcoma, adjuvant radio-
therapy is frequently applied to improve local control.
However, since secondary angiosarcomas develop within a
field of radiation, usually the surrounding tissue has already
received the maximum dose of radiation. In spite of this, one
patient was treated with radiotherapy and initially responded
well to therapy. After a few months, however, the disease
progressed rapidly. A small single-center study (n = 14)
that looked at hyperfractionated and accelerated radiother-
apy (HART), with or without surgical resection, found a
64 % 5-year progression-free survival.9 Other studies
reported a good response to (neo-) adjuvant treatment with
paclitaxel in some patients.12,21,22 Interpretation of these
results is hampered by the limited number of cases and the
heterogeneity of the study populations. Therapies targeting
angiogenesis through the vascular endothelial growth factor
(VEGF) pathway and VEGF receptors (VEGFR) (e.g., sun-
itinib, sorafenib, and bevacizumab) have been promising in
some patients with angiosarcoma; however, they clearly do
not benefit a majority of patients.23
Another important field of study concerns the dose,
extent, and duration of radiotherapy as part of breast-con-
serving therapy. Studies comparing hypofractionated and
conventional fractionation of radiotherapy for breast can-
cer have been conducted, as have studies investigating
radiotherapy for a quadrant of the breast instead of the
entire breast.24–30 If changes in the dose, extent, and
duration of radiotherapy are implemented, the risk of
developing secondary angiosarcoma will have to be mon-
itored closely.
In conclusion, the only chance of curative treatment for
secondary angiosarcoma is extensive surgery, preferably
with resection of all irradiated tissue performed. The rarity
of the disease, its complex behavior, and the need for
extensive surgery indicates that these tumors should be
managed at a tertiary sarcoma center. Despite free margins,
two-thirds of the patients in our study developed a local
recurrence. Surgical intervention in a selected group
improved survival for patients with local recurrence.
However, the median DSS was still only 3 years.
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